1630 related articles for article (PubMed ID: 17984165)
1. Effects of torcetrapib in patients at high risk for coronary events.
Barter PJ; Caulfield M; Eriksson M; Grundy SM; Kastelein JJ; Komajda M; Lopez-Sendon J; Mosca L; Tardif JC; Waters DD; Shear CL; Revkin JH; Buhr KA; Fisher MR; Tall AR; Brewer B;
N Engl J Med; 2007 Nov; 357(21):2109-22. PubMed ID: 17984165
[TBL] [Abstract][Full Text] [Related]
2. Effect of torcetrapib on the progression of coronary atherosclerosis.
Nissen SE; Tardif JC; Nicholls SJ; Revkin JH; Shear CL; Duggan WT; Ruzyllo W; Bachinsky WB; Lasala GP; Tuzcu EM;
N Engl J Med; 2007 Mar; 356(13):1304-16. PubMed ID: 17387129
[TBL] [Abstract][Full Text] [Related]
3. Effect of torcetrapib on carotid atherosclerosis in familial hypercholesterolemia.
Kastelein JJ; van Leuven SI; Burgess L; Evans GW; Kuivenhoven JA; Barter PJ; Revkin JH; Grobbee DE; Riley WA; Shear CL; Duggan WT; Bots ML;
N Engl J Med; 2007 Apr; 356(16):1620-30. PubMed ID: 17387131
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin.
McKenney JM; Davidson MH; Shear CL; Revkin JH
J Am Coll Cardiol; 2006 Nov; 48(9):1782-90. PubMed ID: 17084250
[TBL] [Abstract][Full Text] [Related]
5. Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial.
Bots ML; Visseren FL; Evans GW; Riley WA; Revkin JH; Tegeler CH; Shear CL; Duggan WT; Vicari RM; Grobbee DE; Kastelein JJ;
Lancet; 2007 Jul; 370(9582):153-160. PubMed ID: 17630038
[TBL] [Abstract][Full Text] [Related]
6. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol.
Brousseau ME; Schaefer EJ; Wolfe ML; Bloedon LT; Digenio AG; Clark RW; Mancuso JP; Rader DJ
N Engl J Med; 2004 Apr; 350(15):1505-15. PubMed ID: 15071125
[TBL] [Abstract][Full Text] [Related]
7. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials.
Vergeer M; Bots ML; van Leuven SI; Basart DC; Sijbrands EJ; Evans GW; Grobbee DE; Visseren FL; Stalenhoef AF; Stroes ES; Kastelein JJ
Circulation; 2008 Dec; 118(24):2515-22. PubMed ID: 19029469
[TBL] [Abstract][Full Text] [Related]
8. [Torcetrapib increases mortality in patients with a high risk of cardiovascular disorders].
Rensen PC; Jukema JW
Ned Tijdschr Geneeskd; 2008 May; 152(19):1088-90. PubMed ID: 18552062
[TBL] [Abstract][Full Text] [Related]
9. On- and off-target pharmacology of torcetrapib: current understanding and implications for the structure activity relationships (SAR), discovery and development of cholesteryl ester-transfer protein (CETP) inhibitors.
Johns DG; Duffy J; Fisher T; Hubbard BK; Forrest MJ
Drugs; 2012 Mar; 72(4):491-507. PubMed ID: 22356288
[TBL] [Abstract][Full Text] [Related]
10. Cholesteryl ester transfer protein inhibition, high-density lipoprotein raising, and progression of coronary atherosclerosis: insights from ILLUSTRATE (Investigation of Lipid Level Management Using Coronary Ultrasound to Assess Reduction of Atherosclerosis by CETP Inhibition and HDL Elevation).
Nicholls SJ; Tuzcu EM; Brennan DM; Tardif JC; Nissen SE
Circulation; 2008 Dec; 118(24):2506-14. PubMed ID: 19029466
[TBL] [Abstract][Full Text] [Related]
11. HDL metabolism and CETP inhibition.
Barkowski RS; Frishman WH
Cardiol Rev; 2008; 16(3):154-62. PubMed ID: 18414186
[TBL] [Abstract][Full Text] [Related]
12. Torcetrapib and coronary events.
Cohn LJ
N Engl J Med; 2008 Apr; 358(17):1863; author reply 1863-4. PubMed ID: 18437724
[No Abstract] [Full Text] [Related]
13. Effects of dalcetrapib in patients with a recent acute coronary syndrome.
Schwartz GG; Olsson AG; Abt M; Ballantyne CM; Barter PJ; Brumm J; Chaitman BR; Holme IM; Kallend D; Leiter LA; Leitersdorf E; McMurray JJ; Mundl H; Nicholls SJ; Shah PK; Tardif JC; Wright RS;
N Engl J Med; 2012 Nov; 367(22):2089-99. PubMed ID: 23126252
[TBL] [Abstract][Full Text] [Related]
14. The failure of torcetrapib: was it the molecule or the mechanism?
Tall AR; Yvan-Charvet L; Wang N
Arterioscler Thromb Vasc Biol; 2007 Feb; 27(2):257-60. PubMed ID: 17229967
[No Abstract] [Full Text] [Related]
15. Improving Assessment of Drug Safety Through Proteomics: Early Detection and Mechanistic Characterization of the Unforeseen Harmful Effects of Torcetrapib.
Williams SA; Murthy AC; DeLisle RK; Hyde C; Malarstig A; Ostroff R; Weiss SJ; Segal MR; Ganz P
Circulation; 2018 Mar; 137(10):999-1010. PubMed ID: 28974520
[TBL] [Abstract][Full Text] [Related]
16. Genetic inhibition of CETP, ischemic vascular disease and mortality, and possible adverse effects.
Johannsen TH; Frikke-Schmidt R; Schou J; Nordestgaard BG; Tybjærg-Hansen A
J Am Coll Cardiol; 2012 Nov; 60(20):2041-8. PubMed ID: 23083790
[TBL] [Abstract][Full Text] [Related]
17. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.
Barter P; Gotto AM; LaRosa JC; Maroni J; Szarek M; Grundy SM; Kastelein JJ; Bittner V; Fruchart JC;
N Engl J Med; 2007 Sep; 357(13):1301-10. PubMed ID: 17898099
[TBL] [Abstract][Full Text] [Related]
18. Torcetrapib and atorvastatin: a novel combination therapy for dyslipidemia.
Zareba G
Drugs Today (Barc); 2006 Feb; 42(2):95-102. PubMed ID: 16541186
[TBL] [Abstract][Full Text] [Related]
19. Comparative effects of 10-mg versus 80-mg Atorvastatin on high-sensitivity C-reactive protein in patients with stable coronary artery disease: results of the CAP (Comparative Atorvastatin Pleiotropic effects) study.
Bonnet J; McPherson R; Tedgui A; Simoneau D; Nozza A; Martineau P; Davignon J;
Clin Ther; 2008 Dec; 30(12):2298-313. PubMed ID: 19167589
[TBL] [Abstract][Full Text] [Related]
20. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?
Neeli H; Rader DJ
Cardiol Clin; 2008 Nov; 26(4):537-46. PubMed ID: 18929230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]